NEW YORK – MDxHealth this week reported Q4 2024 preliminary revenues of $24.7 million, up 28 percent from a year ago. Preliminary full-year 2024 revenues were also up 28 percent from a year ago to $90.0 million. In Q4, the firm billed 11,789 tissue-based units and 12,036 liquid-based units. For the full year, it billed 41,586 tissue-based units and 45,700 liquid-based units. For 2025, MDxHealth is issuing revenue guidance of $108 million to $110 million.
ERS Genomics said this week that it is now offering small research enterprises and startups affordable and rapid access to its CRISPR-Cas9 patent portfolio through its Express License platform. Nonexclusive licenses for internal research use are now available to companies with fewer than 15 employees and less than $10 million in funding. Applicants can secure a license by demonstrating their eligibility through scientific credentials such as research publications, academic collaborations, or technology-related patents.
Population genomics and precision health company Helix said this week that TriHealth, Parkview Health, and Rochester Regional Health have joined its Helix Research Network. Each of these health systems plans to enroll 100,000 volunteer participants in the effort, who will receive genetic risk information for conditions such as inherited breast and ovarian cancer, colorectal cancer, and high cholesterol. According to Helix, the health systems will also be able to bring new clinical trials and translational research to their communities through their participation.
Cerca Biotech and Shuwen Biotech said this week that MammaTyper, Cerca's breast cancer molecular subtyping assay, has been included in guidelines for breast cancer diagnosis and treatment by the Chinese Medical Association (CMA) and the China Anti-Cancer Association (CACA). MammaTyper uses real-time PCR to quantify mRNA levels for the breast cancer biomarkers ER, PgR, HER2, and Ki-67 in tumor biopsies or surgical samples to subtype the cancer according to St. Gallen guidelines. The kit has the CE mark, is approved by China's NMPA, and is distributed in China by Shuwen Biotech.
Swedish diagnostics firm Devyser this week released preliminary Q4 2024 results, with net sales of SEK 64.2 million ($5.8 million), up 42 percent from SEK 45.4 million in the year-ago period.
Mayo Clinic Laboratories announced last week that it will offer Lucence’s Liquid Hallmark NGS liquid biopsy assay for circulating tumor DNA and RNA across various cancers. The move is part of Lucence’s continuing effort to expand international access to its testing services.
BGI Genomics said this week that the Brunei Ministry of Health, in partnership with the company, has launched a new National Cervical Cancer Prevention and Control Program along with the 2025 National Guideline to help boost early detection and treatment of cervical cancer across Brunei.
The updated guideline recommends HPV DNA-based testing as a primary tool for early cancer detection. Accordingly, the cancer prevention and control program incorporates a national HPV DNA screening initiative for all women aged 25 to 65. According to BGI Genomics, the HPV self-sampling kits are available at 32 clinics, four hospitals, and three gynecology wards in Brunei's four districts.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.